There have been over 2,000 scientific papers showing that Activated Protein C (’APC’), an endogenous human protein, has potent anti-inflammatory, cytoprotective and regenerative properties. APC has been shown to be an effective therapeutic in numerous diseases - https://pubmed.ncbi.nlm.nih.gov/25824691/. Figure A below illustrates APC’s very effective mechanisms of action on Protease-activated Receptors PAR-1 and PAR-3.
Novapep’s scientists have invented peptide structures which mimic the cell signalling of APC. These peptide structures are significantly cheaper to manufacture than APC and are stable at room temperature, enabling them to be developed as therapeutic drugs. Figure B below illustrates the P1 (TR47) and P3 (3PR) agonist peptides which mimic Activated Protein C’s anti-inflammatory mechanisms of action - https://pubmed.ncbi.nlm.nih.gov/33049092/. Figure C below shows the linked form of P1 and P3 called G10, which generates synergistic cell-signalling effects significantly greater than P1 and P3 individually.
Novapep’s TR47, P3R and G10 PAR agonist peptides and structures herald first in class, easy to use drugs for the treatment of diseases where there are unmet medical needs.
The Griffin & Mosnier Labs are currently undertaking the development and optimisation of G10 structures, to be used for oral and systemic administration in Novapep’s inflammatory bowel disease and cerebral malaria programs. Novapep is undertaking animal studies in its three programs in 2022 and will start final G10 pre-clinical work leading to a Phase 1 clinical trial in 2023.